Detection of Burkholderia pseudomallei O-antigen serotypes in near-neighbor species
- Joshua K Stone1,
- Mark Mayo2,
- Stephanie A Grasso1,
- Jennifer L Ginther1,
- Stephanie D Warrington1,
- Christopher J Allender1,
- Adina Doyle1,
- Shalamar Georgia1,
- Mirjam Kaestli2,
- Stacey M Broomall3,
- Mark A Karavis3,
- Joseph M Insalaco3,
- Kyle S Hubbard3,
- Lauren A McNew3,
- Henry S Gibbons3,
- Bart J Currie2,
- Paul Keim1 and
- Apichai Tuanyok1Email author
© Stone et al.; licensee BioMed Central Ltd. 2012
Received: 28 July 2012
Accepted: 31 October 2012
Published: 5 November 2012
Burkholderia pseudomallei is the etiological agent of melioidosis and a CDC category B select agent with no available effective vaccine. Previous immunizations in mice have utilized the lipopolysaccharide (LPS) as a potential vaccine target because it is known as one of the most important antigenic epitopes in B. pseudomallei. Complicating this strategy are the four different B. pseudomallei LPS O-antigen types: A, B, B2, and rough. Sero-crossreactivity is common among O-antigens of Burkholderia species. Here, we identified the presence of multiple B. pseudomallei O-antigen types and sero-crossreactivity in its near-neighbor species.
PCR screening of O-antigen biosynthesis genes, phenotypic characterization using SDS-PAGE, and immunoblot analysis showed that majority of B. mallei and B. thailandensis strains contained the typical O-antigen type A. In contrast, most of B. ubonensis and B. thailandensis-like strains expressed the atypical O-antigen types B and B2, respectively. Most B. oklahomensis strains expressed a distinct and non-seroreactive O-antigen type, except strain E0147 which expressed O-antigen type A. O-antigen type B2 was also detected in B. thailandensis 82172, B. ubonensis MSMB108, and Burkholderia sp. MSMB175. Interestingly, B. thailandensis-like MSMB43 contained a novel serotype B positive O-antigen.
This study expands the number of species which express B. pseudomallei O-antigen types. Further work is required to elucidate the full structures and how closely these are to the B. pseudomallei O-antigens, which will ultimately determine the efficacy of the near-neighbor B serotypes for vaccine development.
Lipopolysaccharide (LPS) is an amphiphilic molecule which is a major component in the outer membrane of Gram-negative bacteria . It is composed of three parts – a membrane bound lipid A, or endotoxin, a core oligosaccharide, and a repeating O-antigen . The lipid A is the signal that triggers the innate immune system during infection and is structurally conserved across genera with differences in immune response attributable to the presence of varying fatty acids [1, 3, 4]. The O-antigen is the most structurally diverse LPS component within a species, with over 170 known structures in Escherichia coli alone . As an antigenic determinant, O-antigen structures can be grouped by serotype .
Burkholderia pseudomallei is a saprophytic Gram-negative bacterium endemic to Southeast Asia and Australia. It is the etiological agent of the septicemic disease melioidosis and a CDC category B select agent with no available effective vaccine [5, 6]. However, limited success has been met with use of LPS from B. pseudomallei and the avirulent near-neighbor B. thailandensis in rodent and rabbit melioidosis models [7–10]. Four distinct O-antigen ladder patterns have been described in B. pseudomallei, known as types A, B, B2, and rough, which lacks the repeating unit . Most B. pseudomallei strains express type A O-antigen, making it by far the most abundant structure, whereas the atypical types, B and B2, are serologically related but have distinct ladder banding patterns when run on SDS-PAGE . Type A is also found in B. thailandensis and the virulent B. mallei[12, 13]. This is also the only O-antigen that has been structurally characterized, containing a disaccharide 3)-β-D-glucopyranose-(1,3)-6d-α-L-talopyranose-(1 repeat, with the talose residue variably acetylated and methylated [13–16]. Type B has not been found in any other species while type B2 was recently described in a B. thailandensis-like species . B. thailandensis-like species is a new species within the Pseudomallei phylogenetic group which is closely related to B. pseudomallei and B. thailandensis. This new species was first discovered in soil and water in northern Australia . The presence of types A and B2 in near-neighbor species suggests that further screening will reveal additional species expressing B. pseudomallei O-antigen types.
In our present study, LPS genotyping and phenotypic analyses of numerous near-neighbor isolates suggested the presence of type A in B. mallei, B. thailandensis, and B. oklahomensis; type B in B. ubonensis; and type B2 in B. thailandensis, a B. thailandensis-like species, and B. ubonensis. Representative strains containing B. pseudomallei O-antigen ladder banding patterns were chosen for further whole genome sequencing and subjected to comparative genomics.
16S rRNA and recAsequencing
We confirmed bacterial species on all 113 bacterial strains using 16S rRNA and recA sequencing techniques compared to reference strains available in GenBank. Cutoffs of 99% and 94% were established for species classification for 16S and recA analyses, respectively (data not shown). We identified 23 B. mallei, 4 B. oklahomensis, 12 B. thailandensis, 5 B. thailandensis-like species, 44 B. ubonensis, and 25 unidentified Burkholderia species strains.
LPS genotyping (PCR)
Prevalence of four B. pseudomallei O-antigen types in near-neighbors
Total strains tested
Known B. pseudomallei O-antigen
Unidentified Burkholderia spp.
LPS phenotyping (SDS-PAGE, silver staining and immunoblotting)
Twenty-one strains of B. mallei expressed type A O-antigen while the remaining two strains (ATCC10399 and NCTC120) expressed rough type. ATCC10399 was previously described as having an intact ladder [13, 20], but the whole genome sequence (WGS) available in GenBank shows an IS407A insertion in wbiG (NZ_CH899681), which would predict a rough type. IS407A is known as one of the most common insertion sequence (IS) elements in B. pseudomallei and B. mallei. NCTC120’s rough type phenotype is consistent with prior works [13, 20]. Further immunoblotting with the B. mallei LPS-specific mAb 3D11 showed all 21 B. mallei strains with intact ladder profiles bound this antibody while the two rough type strains did not. B. pseudomallei K96243 and B. oklahomensis E0147 bound mAb 3D11, as previously described . Similarly, eight of the B. thailandensis strains bound mAb 3D11 while E264, MSMB59, MSMB60, and 82172 did not (Additional file 1: Table S1). Similarly, testing the strains containing type A with the IgM mAb Pp-PS-W, the B. pseudomallei LPS-specific mAb , showed that B. mallei ATCC23344 and B. oklahomensis E0147 were not seroreactive while B. pseudomallei K96243 was seroreactive. Notably, nine B. thailandensis strains were seroreactive to this mAb, while MSMB59 and MSMB60 were not. This suggested the existence of seroreactivity diversity within B. thailandensis.
PCR suggested that 11 strains of B. ubonensis would be positive for type B O-antigen. Immunoblotting confirmed the expression of type B in all of these, one of which, MSMB57, was selected for genomic analysis. Another strain, B. ubonensis MSMB108, was negative for all genotypes by PCR but displays a ladder pattern identical to the type B2 B. thailandensis-like MSMB122 (Figure 1). We also noted that other tested B. ubonensis strains produced distinct LPS ladder patterns to those of B. pseudomallei, which were not seroreactive (data not shown). Along with B. thailandensis, B. ubonensis was the only species that expressed more than one type of B. pseudomallei O-antigen.
B. thailandensis-like strains expressed two different O-antigen ladder patterns, both of which were B serotypes. Strains MSMB121, 122, 712, and 714 expressed ladder type B2 (Additional file 1: Table S1), whereas strain MSMB43 expressed a novel serologically related O-antigen not found in B. pseudomallei. This O-antigen, like type B2, bound the type B patient’s serum but exhibited a banding pattern unlike either type B or B2 (Figure 1). This is the first description of a seroreactive O-antigen found in a near-neighbor species which is unknown in B. pseudomallei.
Burkholderia sp. MSMB175 was negative for all B. pseudomallei O-antigen types by PCR. The immunoblotting analysis revealed a banding pattern that was similar to type B2 in higher molecular weight bands (Figure 1). The O-antigen biosynthesis gene cluster for this strain was subsequently sequenced and found to be type B2 (GenBank: JQ783347), with a nucleotide identity of 88% compared to B. pseudomallei MSHR840.
Genomic comparison has shown that a homolog of wbiE gene in B. oklahomensis E0147 (BoklE_010100014785) had one and five single nucleotide polymorphisms (SNPs) at the forward and reverse primer binding sites, respectively. This caused negative PCR results when the previously published LPS genotype A primers  were used. In this study, we have adjusted the LPS genotype A primers to be able to amplify all Burkholderia species that contains the LPS genotype A. Similarly, in the type B2 positive Burkholderia sp. MSMB175, two and five SNPs were found in the forward and reverse primer pair binding sites, respectively, revealing why this strain was negative to PCR. In this study, we did not adjust the PCR primers to amplify the LPS genotype B2 in this uncharacterized Burkholderia species.
B. thailandensis E264, MSMB59, and MSMB60 were compared to determine the reason for the differences in sero-reactivity with the mAb Pp-PS-W. Four SNPs were found across the entire gene cluster, however all were synonymous and the amino acid sequences identical (data not shown). In addition, comparison of oacA, the 4-O acetyltransferase gene, sequences also revealed no differences. Further work is required to explain why the Australian isolates fail to cross react with this mAb.
Ten Burkholderia strains were selected for whole genome sequencing to confirm the LPS genotypes. These included B. mallei India 86-567-2, KC237, NCTC120; B. thailandensis MSMB59, MSMB60, 82172; B. thailandensis-like sp. MSMB121, MSMB122; B. ubonensis MSMB57; and Burkholderia sp. MSMB175. Comparative genomics has demonstrated that O-antigen biosynthesis genes in all three sequenced B. mallei strains were very similar to those found in a reference LPS genotype A B. mallei ATCC23344, except that strain NCTC120 had an insertion mutation in its wbiE gene (GenBank: JN581992). We noted that the mutation defects the production of O-antigen ladder pattern in this strain (Additional file 1: Table S1). In addition, genomic analysis has shown that O-antigen genes in B. thailandensis MSMB59 and MSMB60 were very similar to those found in a reference LPS genotype A B. thailandensis E264. Interestingly, B. thailandensis 82172, and B. thailandensis-like sp. strains MSMB121, MSMB122, and Burkholderia sp. MSMB175 had O-antigen genes similar to those found in a reference type B2 B. pseudomallei MSHR840, while B. ubonensis MSMB57 had O-antigen genes which were similar to the genes found in a reference type B B. pseudomallei 576 .
O-antigen type A has been described as a disaccharide glucose-talose repeat in B. pseudomallei, B. mallei, and B. thailandensis and these structures differ only by side group modification. B. pseudomallei modifies the talose residue with a 2-O methyl/4-O acetyl group or with a 2-O acetyl/4-O hydroxyl group [15, 16]. In B. mallei, regardless of whether the 2-O position is methylated or acetylated, the 4-O position remains in its native hydroxyl state . B. thailandensis has been reported to have the same modification patterns as B. pseudomallei[12, 14, 22], but a recent study by Ngugi, et al., suggests that B. thailandensis E264 features a different pattern. Utilizing gas chromatography/mass spectrometry (GC/MS) to examine methylation patterns, they concluded this strain does not methylate the 2-O position. Brett, et al., generated mutants of oacA, the 4-O acetyltransferase gene, which also had the unexpected result of a lack of methylation at the 2-O position. This suggests that the methyl group may be lost during GC/MS or the E264 strain utilized by Ngugi, et al., may have undergone mutation in oacA, losing its methylase capabilities.
In our current study, 21 out of 23 B. mallei strains expressed intact type A O-antigens while the remaining two (ATCC10399 and NCTC120) were rough. Two previous studies showed that B. mallei ATCC10399 had a full ladder pattern by silver staining and immunoblotting [13, 20]. Our genomic analysis has shown that wbiG gene which is known to be involved in the biosynthesis of the type A O-antigen, was disrupted in this strain by IS407A. This supported our finding that ATCC10399 produced rough LPS. B. mallei NCTC120 was also known as a rough LPS type due to the disruption of its wbiE, the glycosyltransferase gene, by IS407A[13, 20]. DNA sequencing of this strain in our current study revealed the absence of this insertion element, however, a 22 base pair artifact remains in the 3′ end of this gene (GenBank: JN581992), suggesting, IS407A remains active in this strain. We believe that the artifact sequence of the IS407A is disruptive enough to yield the same phenotype as the full insertion.
Eleven strains of B. ubonensis, all Australian environmental isolates, were found to express type B. This O-antigen type is present in approximately 14% of all B. pseudomallei isolates of which the vast majority are Australian . We report here the first discovery of B. pseudomallei type B O-antigen in a near-neighbor species. Previously, B. ubonenesis was known in Australia from only two strains, only one of which has been sequenced and contains an unknown O-antigen biosynthesis gene cluster (NZ_ABBE01000374) . Environmental sampling in northern Australia yielded 44 total B. ubonensis strains, which was the species most commonly isolated. Conversely, only two B. thailandensis strains were isolated, the same number as Levy, et al., found . While no study has examined the abundance of B. ubonensis in Southeast Asia, it is possible that these two species occupy a similar environmental niche where B. ubonensis is able to outcompete B. thailandensis in Australia. In support this, B. ubonensis isolated from Papua New Guinea exhibited antibiosis against B. pseudomallei. These Australian isolates may produce a similar compound against B. thailandensis.
B. thailandensis-like species, a new member of the Pseudomallei group, expresses type B2 and a novel ladder pattern seropositive for type B, thus far unknown in any other species or strain. Curiously, B. thailandensis 82172 expresses type B2, as well, marking the first description of another O-antigen type in this species. This strain belongs to a distinct phylogenetic cluster along with four other geographically diverse B. thailandensis strains, only one of which was isolated in Asia. This cluster has been suggested as the beginning of a possible speciation event and the discovery of type B2 LPS lends further credence to this idea .
Burkholderia sp. MSMB175 is another Australian environmental isolate which clusters with the Pseudomallei group on the basis of recA and 16S sequence and may represent a new species (data not shown). The presence of type B2 O-antigen (Table 1) supports the possibility that this strain belongs to the Pseudomallei group.
A 1993 study of northeastern Thai children by Kanaphun, et al., revealed that 80% are seropositive for antibodies against B. pseudomallei by the age of four. Accordingly, over 25% of environmental Burkholderia isolates in Thailand are B. thailandensis. This suggests that some of these children have instead been exposed to this species and not B. pseudomallei, especially given the noted inaccuracies and high background of indirect hemagglutination assays . Little work has examined the seropositive rates in Australia, but two studies in Northern Queensland returned rates of 2.5-5.7% [30, 31]. The high clinical relevance of B. pseudomallei expressing type B or B2 O-antigen, along with the new apparent abundance of these types in Australian near-neighbors, suggest similar exposures may result in false positive diagnoses, as is likely the case in Thailand.
These near-neighbor species are avirulent, B. mallei excepted, and as such are not limited to the biosafety regulations that B. pseudomallei is as a biosafety level 3 (BSL-3) organism. Few laboratories worldwide are properly equipped to handle BSL-3 work and so the finding of B. pseudomallei type LPS in these non-pathogenic Burkholderia species will allow many additional laboratories the opportunity to work towards vaccine development for melioidosis.
B. thailandensis type A O-antigen has been used with some success to vaccinate mice against B. pseudomallei[7–10]. This O-antigen is indistinguishable between these two species in backbone and side group modifications [12, 16, 22]. Given the high genetic similarity between types B and B2 in near-neighbors and B. pseudomallei, it is likely at least one species will be identical in backbone and side group modifications, as well. In such a case, it is possible that particular strain or strains will confer comparable host immunity upon subsequent challenge with type B or B2 B. pseudomallei in much the same way B. thailandensis protects against type A B. pseudomallei challenge.
Bacterial strains, DNA, and LPS preparations
A total of 113 strains of B. pseudomallei near-neighbors were used in this study. These included 23 B. mallei, 4 B. oklahomensis, 12 B. thailandensis, 5 B. thailandensis-like species, 44 B. ubonensis, and other 25 Burkholderia strains (Tables 1 and Additional file 1: Table S1). Species identification was made on the basis of recA and 16S rRNA sequences [17, 18]. B. pseudomallei strains K96243, 576, MSHR840, and MSHR1655 were used as references for the O-antigen types A, B, B2, and rough, respectively . All strains were grown on Luria-Bertani (LB) agar (Difco, USA) for DNA and LPS extractions. DNA was extracted using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA), according to the manufacturer’s instructions. LPS was extracted using whole-cell lysis according to a previous method [11, 20] and separated by SDS-PAGE (Invitrogen, USA).
Strains were genotyped for B. pseudomallei O-antigen types via multiplex-SYBR-Green real-time PCR in accordance with as previously reported . As the previously published sequences did not detect all near-neighbors expressing type A, this primer pair was redesigned. The new type A primer pair spans the intergenic space of wbiD and wbiE and the primer sequences are: LPSA_For, 5′-ACGGGATCGTACAGTTTCGGATGCT-3′; and LPSA_ Rev, 5′-GAAGATCGTCGCTCGGAGAATCGT-3′.
Silver staining and serology
Silver staining was first used to validate B. pseudomallei O-antigen type presence in near-neighbor strains, following the previously determined criteria for identification [11, 20]. Samples were then screened for sero-crossreactivity using sera from two Australian melioidosis patients, one serum sample per immunoblot analysis. One patient was infected by B. pseudomallei MSHR1328 expressing type A O-antigen, while another patient was infected by strain MSHR1079 which expressed type B O-antigen . The same samples were also tested serologically using the commercially available monoclonal antibody (mAb) 3D11 (Fitzgerald Industries International Inc., USA), specific to B. mallei LPS . Additionally, LPS samples from all B. thailandensis strains were also tested using mAb Pp-PS-W  which is specific to B. pseudomallei type A O-polysaccharide (O-PS).
The susceptibility of the near-neighbor strains to 30% normal human serum (NHS; Lonza Group LtD., USA) was tested according to a previous method [11, 23]. Briefly, strains were grown at 37°C overnight with shaking in LB broth and cell concentrations were equilibrated. A 1:1,000 dilution of culture was created in TSB-DC (Trypticase soy broth dialysate –treated with Chelex-100) media , and grown for five hours. A 1:6:3 vol. ratio of the culture: TSB-DC media:undiluted NHS was incubated for two hours at 37°C with no shaking. Total bacterial plate counting was performed on these cultures. E. coli HB101 was used as a negative control.
Whole genome sequencing and genomic analysis
Whole genome sequencing was performed using 454 sequencing technology (Roche, USA) by the US Army Edgewood Chemical Biological Center (ECBC), Aberdeen, MD. O-antigen biosynthesis gene cluster annotations were made in comparison to the aforementioned reference B. pseudomallei types using the BLAST program and Artemis Comparison Tool (ACT) . Annotated O-antigen gene sequences of B. mallei strains India 86-567-2, KC237, NCTC120; B. thailandensis strains MSMB59, MSMB60, 82172; B. thailandensis-like species strains MSMB121, MSMB12; B. ubonensis strain MSMB57; and unidentified Burkholderia sp. strain MSMB175, were assigned GenBank accessions: JN581990, JN581991, JN581992, JN581997, JN581998, JQ783347, HQ908420, JF745809, JF745807, and JF745808, respectively.
This work was funded by the US Department of Homeland Security contract no. HSHQDC-10-C-00135 to AT.
- Raetz CRH, Whitfield C: Lipopolysaccharide endotoxins. Annu Rev Biochem. 2002, 71: 635-700. 10.1146/annurev.biochem.71.110601.135414.PubMedPubMed CentralView Article
- Caroff M, Karibian D: Structure of bacterial lipopolysaccharides. Carbohydr Res. 2003, 338 (23): 2431-2447. 10.1016/j.carres.2003.07.010.PubMedView Article
- Alexander C, Rietschel ET: Invited review: bacterial lipopolysaccharides and innate immunity. J Endotoxin Res. 2001, 7 (3): 167-202.PubMed
- Novem V, Shui G, Wang D, Bendt AK, Sim SH, Liu Y, Thong TW, Sivalingam SP, Ooi EE, Wenk MR, et al: Structural and biological diversity of lipopolysaccharides from Burkholderia pseudomallei and Burkholderia thailandensis. Clin Vaccine Immunol. 2009, 16 (10): 1420-1428. 10.1128/CVI.00472-08.PubMedPubMed CentralView Article
- Cheng AC, Currie BJ: Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev. 2005, 18 (2): 383-416. 10.1128/CMR.18.2.383-416.2005.PubMedPubMed CentralView Article
- Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM: Public health assessment of potential biological terrorism agents. Emerg Infect Dis. 2002, 8 (2): 225-230. 10.3201/eid0802.010164.PubMedPubMed CentralView Article
- Brett P, Woods D: Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates. Infect Immun. 1996, 64 (7): 2824-2828.PubMedPubMed Central
- Jones SM, Ellis JF, Russell P, Griffin KF, Oyston PCF: Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J Med Microbiol. 2002, 51 (12): 1055-1062.PubMedView Article
- Nelson M, Prior JL, Lever MS, Jones HE, Atkins TP, Titball RW: Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J Med Microbiol. 2004, 53 (12): 1177-1182. 10.1099/jmm.0.45766-0.PubMedView Article
- Ngugi SA, Ventura VV, Qazi O, Harding SV, Kitto GB, Estes DM, Dell A, Titball RW, Atkins TP, Brown KA, et al: Lipopolysaccharide from Burkholderia thailandensis E264 provides protection in a murine model of melioidosis. Vaccine. 2010, 28 (47): 7551-7555. 10.1016/j.vaccine.2010.08.058.PubMedView Article
- Tuanyok A, Stone JK, Mayo M, Kaestli M, Gruendike J, Georgia S, Warrington S, Mullins T, Allender CJ, Wagner DM, et al: The genetic and molecular basis of O-antigenic diversity in Burkholderia pseudomallei lipopolysaccharide. PLoS Negl Trop Dis. 2012, 6 (1): e1453-10.1371/journal.pntd.0001453.PubMedPubMed CentralView Article
- Brett PJ, DeShazer D, Woods DE: Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species. Int J Syst Bacteriol. 1998, 48 (1): 317-320. 10.1099/00207713-48-1-317.PubMedView Article
- Burtnick MN, Brett PJ, Woods DE: Molecular and physical characterization of Burkholderia mallei O Antigens. J Bacteriol. 2002, 184 (3): 849-852. 10.1128/JB.184.3.849-852.2002.PubMedPubMed CentralView Article
- Brett PJ, Burtnick MN, Heiss C, Azadi P, DeShazer D, Woods DE, Gherardini FC: Burkholderia thailandensis oacA mutants facilitate the expression of Burkholderia mallei-Like O Polysaccharides. Infect Immun. 2011, 79 (2): 961-969. 10.1128/IAI.01023-10.PubMedPubMed CentralView Article
- Knirel YA, Paramonov NA, Shashkov AS, Kochetkov NK, Yarullin RG, Farber SM, Efremenko VI: Structure of the polysaccharide chains of Pseudomonas pseudomallei lipopolysaccharides. Carbohydr Res. 1992, 233: 185-193.PubMedView Article
- Perry M, MacLean L, Schollaardt T, Bryan L, Ho M: Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei. Infect Immun. 1995, 63 (9): 3348-3352.PubMedPubMed Central
- Gee JE, Glass MB, Novak RT, Gal D, Mayo MJ, Steigerwalt AG, Wilkins PP, Currie BJ: Recovery of a Burkholderia thailandensis-like isolate from an Australian water source. BMC Microbiol. 2008, 8: 54-10.1186/1471-2180-8-54.PubMedPubMed CentralView Article
- Godoy D, Randle G, Simpson AJ, Aanensen DM, Pitt TL, Kinoshita R, Spratt BG: Multilocus sequence typing and evolutionary relationships among the causative agents of melioidosis and glanders, Burkholderia pseudomallei and Burkholderia mallei. J Clin Microbiol. 2003, 41 (5): 2068-2079. 10.1128/JCM.41.5.2068-2079.2003.PubMedPubMed CentralView Article
- Glass MB, Steigerwalt AG, Jordan JG, Wilkins PP, Gee JE: Burkholderia oklahomensis sp. nov., a Burkholderia pseudomallei-like species formerly known as the Oklahoma strain of Pseudomonas pseudomallei. Int J Syst Evol Microbiol. 2006, 56 (9): 2171-2176. 10.1099/ijs.0.63991-0.PubMedView Article
- Woods DE, Jeddeloh JA, Fritz DL, DeShazer D: Burkholderia thailandensis E125 harbors a temperate bacteriophage specific for Burkholderia mallei. J Bacteriol. 2002, 184 (14): 4003-4017. 10.1128/JB.184.14.4003-4017.2002.PubMedPubMed CentralView Article
- Tuanyok A, Leadem BR, Auerbach RK, Beckstrom-Sternberg SM, Beckstrom-Sternberg JS, Mayo M, Wuthiekanun V, Brettin TS, Nierman WC, Peacock SJ, et al: Genomic islands from five strains of Burkholderia pseudomallei. BMC Genomics. 2008, 9: 566-10.1186/1471-2164-9-566.PubMedPubMed CentralView Article
- Brett PJ, Burtnick MN, Woods DE: The wbiA locus is required for the 2-O-acetylation of lipopolysaccharides expressed by Burkholderia pseudomallei and Burkholderia thailandensis. FEMS Microbiol Lett. 2003, 218 (2): 323-328. 10.1111/j.1574-6968.2003.tb11536.x.PubMedView Article
- DeShazer D, Brett PJ, Woods DE: The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Mol Microbiol. 1998, 30 (5): 1081-1100. 10.1046/j.1365-2958.1998.01139.x.PubMedView Article
- Levy A, Merritt AJ, Aravena-Roman M, Hodge MM, Inglis TJJ: Expanded Range of Burkholderia Species in Australia. AmJTrop Med Hyg. 2008, 78 (4): 599-604.
- Marshall K, Shakya S, Greenhill AR, Padilla G, Baker A, Warner JM: Antibiosis of Burkholderia ubonensis against Burkholderia pseudomallei, the causative agent for melioidosis. Southeast Asian J Trop Med Public Health. 2010, 41 (4): 904-912.PubMed
- Sim BMQ, Chantratita N, Ooi WF, Nandi T, Tewhey R, Wuthiekanun V, Thaipadungpanit J, Tumapa S, Ariyaratne P, Sung W-K, et al: Genomic acquisition of a capsular polysaccharide virulence cluster by non-pathogenic Burkholderia isolates. Genome Biol. 2010, 11 (8): R89-10.1186/gb-2010-11-8-r89.PubMedPubMed CentralView Article
- Kanaphun P, Thirawattanasuk N, Suputtamongkol Y, Naigowit P, Dance DAB, Smith MD, White NJ: Serology and carriage of pseudomonas pseudomallei: a prospective study in 1000 hospitalized children in Northeast Thailand. J Infect Dis. 1993, 167 (1): 230-233. 10.1093/infdis/167.1.230.PubMedView Article
- Smith M, Angus B, Wuthiekanun V, White N: Arabinose assimilation defines a nonvirulent biotype of Burkholderia pseudomallei. Infect Immun. 1997, 65 (10): 4319-4321.PubMedPubMed Central
- Harris PNA, Ketheesan N, Owens L, Norton RE: Clinical features that affect indirect-hemagglutination-assay responses to Burkholderia pseudomallei. Clin Vaccine Immunol. 2009, 16 (6): 924-930. 10.1128/CVI.00026-09.PubMedPubMed CentralView Article
- Ashdown LR, Guard RW: The prevalence of human melioidosis in Northern Queensland. AmJTrop Med Hyg. 1984, 33 (3): 474-478.
- Lazzaroni SM, Barnes JL, Williams NL, Govan BL, Norton RE, LaBrooy JT, Ketheesan N: Seropositivity to Burkholderia pseudomallei does not reflect the development of cell-mediated immunity. Trans R Soc Trop Med Hyg. 2008, 102 (Supplement 1): S66-S70.PubMedView Article
- Ohman DE, Sadoff JC, Iglewski BH: Toxin A-deficient mutants of Pseudomonas aeruginosa PA103: isolation and characterization. Infect Immun. 1980, 28 (3): 899-908.PubMedPubMed Central
- Carver TJ, Rutherford KM, Berriman M, Rajandream MA, Barrell BG, Parkhill J: ACT: the artemis comparison tool. Bioinformatics. 2005, 21 (16): 3422-3423. 10.1093/bioinformatics/bti553.PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.